How Is Insulin Resistance Tested? The Blood Panels, the HOMA-IR Score, and What the Numbers Mean

Short Answer

There isn’t one single insulin resistance test that directly “measures” insulin resistance in routine care. In a clinic, your body’s insulin response is usually estimated from bloodwork: fasting glucose, fasting insulin, and often a calculated HOMA-IR score, which uses fasting insulin and fasting glucose as a research-style estimate of insulin resistance. Clinicians also look at HbA1c, which reflects your average blood glucose over the past 2–3 months, and may order an oral glucose tolerance test (OGTT) when they need to see how your body handles a glucose load over time. (niddk.nih.gov)

For diagnosis, the cutoffs are about blood glucose status, not a standalone insulin-resistance label, and they are used by a clinician for screening and diagnosis — not for self-diagnosis. In the ADA’s Standards of Care, diabetes in nonpregnant people can be diagnosed with A1c ≥6.5%, fasting plasma glucose ≥126 mg/dL after at least 8 hours without calories, or 2-hour plasma glucose ≥200 mg/dL during a 75-g OGTT; prediabetes is typically A1c 5.7–6.4%, fasting glucose 100–125 mg/dL, or 2-hour OGTT glucose 140–199 mg/dL. These results usually need clinical interpretation and, in many cases, confirmation with repeat testing. (pmc.ncbi.nlm.nih.gov)

A wearable can’t confirm insulin resistance because it doesn’t test insulin or glucose in your blood. What it can do is show patterns — higher resting heart rate, lower HRV, disrupted sleep, poorer recovery — that may travel with metabolic stress and may be a useful nudge to ask your clinician whether bloodwork makes sense. The FDA has specifically warned that smartwatches and smart rings should not be used to measure blood glucose on their own, and that accurate glucose decisions should rely on appropriate FDA-authorized devices and medical guidance. (fda.gov)

Insulin-resistance and diabetes tests at a glance

An insulin resistance test usually isn’t one single “yes/no” blood draw. In routine care, clinicians look at glucose-based diabetes tests first, then may add fasting insulin and a formula like HOMA-IR to estimate how hard your body is working to keep blood sugar in range. A higher insulin signal can show up before glucose crosses a diabetes threshold — but fasting insulin and HOMA-IR still need clinical context, not self-diagnosis. (niddk.nih.gov)

What "insulin resistance" is — and why it's estimated, not measured directly

Diabetes is fundamentally a disorder of how your body handles fuel. As one 2026 review puts it, “Diabetes mellitus (DM) is a global metabolic disorder characterized by disturbed glucose and lipid metabolism and persistent hyperglycemia” (Liu, Phytotherapy Research, 2026). (onlinelibrary.wiley.com) Insulin resistance is usually an earlier metabolic strain: your muscle, fat, and liver cells do not respond to insulin as well as they should, so glucose has a harder time moving from your blood into your cells. To compensate, your pancreas makes more insulin. For a while, that extra insulin can keep blood glucose looking “normal” — which is why an insulin resistance test often looks beyond glucose alone. (niddk.nih.gov)

The direct gold-standard way to measure insulin resistance is the hyperinsulinemic-euglycemic clamp. In that test, insulin is infused while glucose is carefully adjusted to hold blood sugar steady, so researchers can see how much glucose the body needs to maintain that balance. It is precise, but it is also long, complex, IV-based, and built for research settings rather than routine primary care. (pmc.ncbi.nlm.nih.gov)

That is why everyday care usually estimates insulin resistance from fasting blood work instead of measuring it directly. The most common estimate is HOMA-IR — the Homeostatic Model Assessment of Insulin Resistance — calculated from fasting glucose and fasting insulin. The usual formula is: HOMA-IR = fasting insulin × fasting glucose ÷ 405 when glucose is reported in mg/dL, or fasting insulin × fasting glucose ÷ 22.5 when glucose is reported in mmol/L. (pmc.ncbi.nlm.nih.gov) HOMA-IR is the number that metabolic research routinely tracks as the working readout of insulin resistance — a research metric, not a treatment recommendation or a stand-alone diagnosis.

A “good” insulin resistance score is therefore not one universal number. Lower HOMA-IR generally means better insulin sensitivity, but reference ranges and cutoffs depend on the population, the lab method, and the insulin assay. One population study proposed 2.29 as a 75th-percentile cutoff in adults without known diabetes or dysglycemia, while other reference-interval studies report different thresholds by population and insulin assay. Broader reviews emphasize that there is still no single scientific consensus cutoff, so your result should be interpreted with your fasting glucose, HbA1c, triglycerides, HDL cholesterol, waist/BMI pattern, medications, symptoms, and risk factors — not as a stand-alone diagnosis. (pmc.ncbi.nlm.nih.gov)

The blood tests clinicians actually order

Fasting plasma glucose. This is blood sugar after at least 8 hours without food or drink other than water. Clinicians often start here because it is simple, cheap, and directly shows whether glucose is already running high in the fasting state. In ADA criteria, fasting plasma glucose is normal below 100 mg/dL, in the prediabetes range at 100–125 mg/dL, and in the diabetes range at 126 mg/dL or higher; a diabetes-range result is usually repeated on another day unless symptoms and glucose levels make the diagnosis clear. It is also one of the two values used to calculate HOMA-IR. (diabetes.org)

HbA1c (glycated hemoglobin). HbA1c looks backward instead of capturing one morning. It reflects your average blood glucose over roughly the last 2 to 3 months, so you do not need to fast, and it is convenient when a clinician wants a broader view of glucose exposure. ADA cutoffs are below 5.7% for normal, 5.7% to 6.4% for prediabetes, and 6.5% or higher for diabetes. The useful part is the long window; the limitation is that anything affecting red blood cells or hemoglobin can make A1c less reliable, so your clinician may pair it with glucose testing. (diabetes.org)

Fasting insulin + HOMA-IR. Fasting insulin shows how hard your pancreas may be working to keep glucose steady, but by itself it is hard to interpret because insulin assays and “normal” ranges vary. HOMA-IR combines fasting insulin with fasting glucose: HOMA-IR = fasting glucose in mmol/L × fasting insulin in µU/mL ÷ 22.5. If your lab reports glucose in mg/dL, it has to be converted to mmol/L first. HOMA-IR is a research-backed surrogate for insulin resistance, not a standalone diagnosis; commonly cited “insulin-resistant” cutoffs often sit around 2.0–2.5, but the right threshold depends on the population, lab method, and clinical context. (pmc.ncbi.nlm.nih.gov)

Oral glucose tolerance test (OGTT). The OGTT stresses the system on purpose. You drink a measured glucose solution, then blood sugar is checked 2 hours later to see how well your body clears that glucose load. ADA criteria define the 2-hour OGTT result as normal below 140 mg/dL, prediabetes at 140–199 mg/dL, and diabetes at 200 mg/dL or higher. Clinicians may use it when fasting glucose or A1c does not tell the whole story, and it is also the standard framework used for glucose testing in pregnancy. (diabetes.org)

Supporting labs. A lipid panel and inflammation markers do not diagnose insulin resistance, but they can show the metabolic pattern around it. High triglycerides, low HDL cholesterol, high fasting glucose, and abdominal weight gain often travel together as part of metabolic syndrome — sometimes called insulin resistance syndrome. A triglyceride-to-HDL pattern can therefore support the picture, especially when glucose and insulin results are borderline. Inflammatory markers such as high-sensitivity C-reactive protein can also rise alongside insulin resistance, but they are context clues, not an insulin resistance test. (medlineplus.gov)

What the numbers mean — and why one reading isn't a diagnosis

An insulin resistance test can give you useful signals, but a single number is not the same as a diagnosis. Blood glucose and insulin move with sleep, stress, illness, exercise, timing of the last meal, and the normal noise of lab measurement. That is why diabetes confirmation is not built on one lonely abnormal result: NIDDK’s clinician guidance says diagnosis of type 2 diabetes or prediabetes requires two abnormal test results, either from the same sample or from different samples; clinicians can repeat the same test or run a different diagnostic test, and if two tests conflict, they repeat the one above the diagnostic threshold. NIDDK’s patient guidance puts the same idea more simply: any test used to diagnose diabetes needs a second measurement unless there are clear symptoms of diabetes. (niddk.nih.gov)

HbA1c has a special caveat because it is tied to hemoglobin inside red blood cells. If red blood cells are being made, lost, destroyed, or replaced differently than usual, the A1c can drift away from your true average glucose. Severe anemia, blood loss or transfusion, sickle cell disease or thalassemia, kidney or liver disease, and early or late pregnancy can falsely raise or lower A1c; NIDDK also notes that pregnancy, some types of anemia, and other blood problems can make A1c inaccurate. That is why clinicians often cross-check A1c with fasting plasma glucose or an OGTT instead of treating one percentage as the whole story. (cdc.gov)

The takeaway: your numbers matter, but the pattern matters more. A result that is high, borderline, or out of step with how you feel is a reason to retest, compare methods, and interpret the results with your full clinical picture — not a verdict you have to carry home from one blood draw.

Can a wearable or Apple Watch detect insulin resistance or diabetes?

No. A wearable — including Welltory, Apple Watch, a smartwatch, or a smart ring — does not measure blood glucose or insulin, and it cannot diagnose insulin resistance, prediabetes, or diabetes. Those conditions are checked with blood tests, such as A1C, fasting blood sugar, an oral glucose tolerance test, or a random blood sugar test; they are not diagnosed from heart rate, HRV, sleep, or “readiness” patterns. (cdc.gov) The FDA has also warned that it has not authorized, cleared, or approved any smartwatch or smart ring that measures or estimates blood glucose on its own, and that these devices are different from FDA-authorized glucose meters or continuous glucose monitors. (fda.gov)

What a wearable can do is track physiology that often shifts when your body is under metabolic strain: resting heart rate, heart-rate variability (HRV), heart-rate recovery after effort, and sleep quality. These signals come from the autonomic nervous system — the part of your body that helps switch between “push” mode and “recover” mode. Insulin resistance can overlap with that system because fuel handling, inflammation, blood vessels, and nervous-system tone are not separate silos in the body. In a 2026 analysis of 1,588 people in a heart-failure cohort study (the MyoVasc study), a higher HOMA-IR — a blood-based insulin resistance score — was associated with lower 60-second heart-rate recovery even after adjustment for HbA1c; C-peptide, another insulin-status marker, also tracked with lower recovery-side cardiac autonomic activity. The paper concludes that its results demonstrate “the relevance of insulin status for vagal activity of cardiac autonomic function” (Cardiovascular Diabetology, 2026). (pmc.ncbi.nlm.nih.gov)

That matters, but it does not turn your watch into an insulin resistance test. It means that if your wearable trends keep moving in the wrong direction — higher resting heart rate, lower HRV, poorer recovery, worse sleep, especially alongside weight gain, fatigue after meals, increased thirst, frequent urination, or a strong family history — that pattern can be a useful nudge to ask your clinician whether bloodwork makes sense. A continuous glucose monitor is a separate medical device category: it measures glucose in real time from interstitial fluid under the skin, while a standard smartwatch or ring does not directly test blood glucose. (cdc.gov)

Who should get tested — and why it's often missed early

Insulin resistance can sit in the background for years because your pancreas may compensate by making more insulin, keeping glucose “normal enough” while your tissues are already pushing back. That is why an insulin resistance test is usually triggered by risk, not by waiting until you feel different. In the ADA’s Standards of Care, screening for prediabetes and type 2 diabetes should begin no later than age 35 for everyone; it should also be considered at any adult age if you have overweight or obesity — commonly BMI ≥25, or ≥23 in people of Asian ancestry — plus another risk factor such as a first-degree family history, prior gestational diabetes, PCOS, physical inactivity, hypertension, dyslipidemia, acanthosis nigricans, fatty liver/metabolic dysfunction–associated steatotic liver disease, HIV, pancreatitis, periodontal disease, or exposure to medicines that can push glucose up. If results are normal, repeat testing is generally done at least every 3 years, sooner if your risk changes; if you already have prediabetes, testing is usually yearly. (pmc.ncbi.nlm.nih.gov)

Risk is not only about weight. Illness can raise it too. In a large 2026 population-based cohort in British Columbia, Canada, following SARS-CoV-2 infection, “the risk of diabetes was higher among infected individuals (HR 1.18; 95% CI: 1.15-1.22; p < 0.0001), rising progressively with illness severity—from ambulatory to hospitalised and intensive-care cases” (Diabetes/Metabolism Research and Reviews, 2026) — a useful reminder that new fatigue, thirst, weight change, higher resting heart rate, worse sleep, or a harder recovery after serious illness may be a reason to ask for blood testing rather than assuming your metabolism is fine. (onlinelibrary.wiley.com)

And if you live with type 1 diabetes, insulin resistance still matters. Type 1 and type 2 diabetes are different diseases, but high glucose pressure, blood pressure, body fat, lipids, inflammation, and kidney strain can travel through overlapping pathways. A 2026 review on chronic kidney disease in type 1 diabetes puts it plainly: “The development and progression of CKD in people with T1D are driven by a constellation of risk factors such as hyperglycemia, hypertension, obesity, and others that share common mechanistic links with T2D” (Diabetes, Obesity and Metabolism, 2026). (dom-pubs.onlinelibrary.wiley.com) That is why “screening” is not just a checkbox for diabetes diagnosis — it is a way for a clinician to catch the metabolic load on your blood vessels, kidneys, and heart before symptoms make it obvious.

Using wearable data to have a better conversation with your doctor

You cannot test yourself for insulin resistance with a watch, ring, or app. But you can walk into the appointment with a clearer story. If your log shows your resting heart rate creeping up, HRV trending down, or sleep getting worse over several weeks — especially if that comes with fatigue, unusual thirst, frequent urination, stronger hunger, brain fog, or afternoon crashes — that pattern is worth bringing to a clinician. Wearable heart-rate and sleep data can help you notice that something has changed, but it should not be used in place of medical care or to self-diagnose a disease. (my.clevelandclinic.org)

The reason is physiological, not magical. Heart rate and HRV are tied to your autonomic nervous system — the “speed up / slow down” control layer that responds to stress, sleep debt, illness, fitness, medications, pain, alcohol, dehydration, and metabolic strain. Lower HRV or a higher resting heart rate can be a useful signal that your body is working harder than usual, but it is not specific enough to say “this is insulin resistance.” Research does show links between HRV and insulin resistance measures, which is why the signal can be relevant context — just not a diagnosis. (my.clevelandclinic.org)

Use the trend as the question: “Should we check my metabolic labs?” Then let bloodwork answer. A clinician may consider fasting glucose, HbA1c, fasting insulin with a HOMA-IR calculation, or an oral glucose tolerance test depending on your symptoms, risk factors, medications, pregnancy status, and past results. HbA1c, fasting plasma glucose, and OGTT are standard blood tests used to screen for or diagnose prediabetes and diabetes; HOMA-IR is an estimate calculated from fasting glucose and fasting insulin, not a direct at-home measurement of insulin resistance. (cdc.gov)

Where Welltory fits: Welltory and a compatible wearable can help you track resting-heart-rate, HRV, recovery, and sleep patterns over time and bring clearer observations to a clinician. It does not measure blood glucose or insulin, and it does not diagnose insulin resistance, prediabetes, or diabetes, confirm a metabolic condition, or replace fasting glucose, HbA1c, an OGTT, fasting insulin, or a clinician’s interpretation of your labs.

How we made it

Made with AI tools, then edited, fact-checked, and medically reviewed by the Welltory team.

Discounts for blog readers: up to 36% off

See what affects your energy, stress, sleep, and daily state with Welltory

Explore your data